Behind The Mystery unveils the world of Rare and Genetic Diseases
Share!
May 22, 2013
Add Comment!
Latest From CheckOphan.org
Oncolytics Biotech® Inc. Meets Primary Endpoint For First Stage Of U.S. Phase 2 Metastatic Melanoma Trial
Oncolytics Biotech Inc. ("Oncolytics") announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 020). The Principal Investigator is Dr. Devalingam Eligi...Read more!
Oncopeptides Secures Venture Funding For Phase II Trial Of Melflufen In Multiple Myeloma Patients
Oncopeptides AB, a company working to enhance oncology therapies, announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; members of Oncopeptides' management and Board also T...Read more!
Medtronic Finds TAVI With CoreValve System Cost Effective For Treating Patients With Severe Aortic Stenosis
Focused on offering devices that provide both clinical and economic value, Medtronic, Inc. unveiled the results of a cost-effectiveness model comparing transcatheter aortic valve implantation with the CoreValve System to medical managementPresented at EuroPCR 2013, the United Kingdom-based analysi...Read more!
The road to diagnosis and treatment for patients with rare and genetic diseases is one with very little navigation. With over 7,000 rare diseases and one in every ten people diagnosed - chances are you know someone, or may even BE someone with a rare disease.
When fewer than 200,000 patients struggle with a disease-- who serves to educate, empower, and lead the sick to the right doctors, the right medications and the fastest road to relief?
Behind the Mystery of: Rare and Genetic Diseases is a series produced with the intention of introducing and uniting patient, physician, and scientist with research, education and opportunity to revolutionize the way our health care system works for the Rare and Genetic Minority.
By partnering with The Global Genes Project, The Balancing Act is able to provide available support to patients diagnosed with rare and genetic diseases, and to give hope with news of clinical trials and new treatments. Together, we can begin a new wave of advocacy and support for the rare community.
The Balancing Act supports and celebrates patient advocacy groups and industry leaders, who inspire connect and guide patients as they move forward through their journey towards treatments and a cure.
Past Segments
Cushings Syndrome
Cystinosis Research Network
Cancer of Unknown or Uncertain Primary
Hereditary AT Deficency
The Global Genes Project
Pulmonary Fibrosis
LAL Deficiency
